Association of TLR-2 gene polymorphisms with susceptibility to Pulmonary Tuberculosis at Northwest Ethiopian population, a case control study

1 Background#

Tuberculosis (TB) is one of the most communicable diseases caused by Mycobacterium tuberculosis (MTB). It is an intracellular pathogen transmitted by inhalation of aerosolized droplets containing bacteria (1). It is a global public health problem that has killed more people than any other bacterial pathogen in human history (2). According to a report from the World Health Organization (WHO), 10.6 million people were affected by TB worldwide, which increased by 4.5% from 10.1 million as compared to 2020 reports. A total of 1.6 million people died from TB in 2021. Globally, TB is the 13th leading cause of death and the second leading infectious cause of death after coronavirus disease-19 ( above HIV) (3).

The earliest encounter between host and pathogen in TB occurs at the interface between innate immune cells and MTB (4). The innate immunity to MTB is mediated by a variety of germ line-encoded pattern recognition receptors (PRRs) (5). Toll-like receptors (TLRs) are one subset of PRRs that are a cornerstone for the innate immune response (6). The TLRs are a trans-membrane protein family with leucine-rich repeats (LRR) and toll-interleukin 1 receptor (TIR) domains (7). The TLRs that play a critical role in MTB recognition are TLR2 (8). Toll-like receptor 2 can recognize a wide range of mycobacterial PAMPs, including lipoarabinomannan (LAM), lipomannan (LM), and phosphatidylinositol dimannoside (PIMs) (9). Toll Like Receptor 2 can form heterodimers with both TLR1 and TLR6 (10), which recognizes triacylated and diacylated lipopeptides, respectively (11).

After recognizing PAMPs in a particular cell type, the cytosolic TIR domain associated with myeloid differentiation protein 88 (MyD88) and Toll/IL-1R domain-containing adaptor-inducing IFN-β (TRIF) adaptor molecules are activated. Then, MyD88 recruits interleukin 1 receptor-associated kinase 4 (IRAK- 4) that phosphorylates IRAK1, which in turn activates TNF receptor-associated factor 6 (TRAF6). Both proteins leave the receptor complex and interact with TGF-β-activated kinase 1 (TAK1). Then, TAK1 becomes phosphorylated and activates the I-κB kinase (IKK) complex comprising IKKα, IKKβ, and IKKγ, and mitogen-activated protein kinase (MAPK) leading to the activation of NF-κB and c-Jun N-terminal kinases (JNK) transcription factor signaling pathways, respectively (12). The activation of these transcription factor signaling cascades promotes the production of pro-inflammatory cytokines (IL- 6, IL-12, TNF-α), type I interferon, and chemokine expression; and plays an essential role in the modulation of the host’s innate and adaptive immunity (13).

Toll like receptor 2 is a membrane protein that is expressed on the surface of cells, encoded by the TLR2 gene, which has four exons and is located on chromosome 4q31-33 in humans. It encodes a protein with 784 amino acid residues (14). Theoretically, any genetic variation in the LRR and TIR domains could influence how TLR molecules recognize the PAMPs and translate their signals (15). The most studied single nucleotide polymorphisms (SNPs) found on the conserved TIR domain in the C-terminal end of the TLR2 gene is G2258A (rs5743708) (16). It is a non-synonymous SNP that causes amino acid substitution from arginine (Arg) to glutamine (Gln) at the position of 753 (Arg⁷⁵³ Glu) (16). The Arg⁷⁵³ Glu polymorphism could resulting in impaired tyrosine phosphorylation of TLR2, TLR2-TLR6 dimerization, suppression of transcription factors such as NF-κB activation, and decreasing secretion of important inflammatory mediators (17). It leads to a reduced response of macrophages to bacterial peptides and results in an attenuation of the host immune response, thus increasing susceptibility to TB (18, 19, 20).

Another SNP found in the extracellular domain of the LRR of TLR2 is T597C, located at the position of 199 (Asn¹⁹⁹ Asn). It is a synonymous SNP that did not result asparagine (Asn) amino acid alteration (21). Synonymous SNPs can modulate mRNA structure (22), influence protein folding, and ultimately alter protein function (23). This type of SNP may also lower TLR expression, attenuate the host’s innate immune response, and result in decreased macrophage function in response to infection with MTB (21).

According to estimates, approximately 90% of TB infected individuals will stay asymptomatic with latent infection (24), whereas only 10% of persons infected with MTB will develop active TB disease at some point in their lives, implying that the majority of those infected have a protective immune response (24, 25). Different studies concluded that TB is a genetically primed and determined infectious disease, and the host genetic polymorphism is the mechanism that leads to the progression from infection to TB disease (26, 27, 28).

Host genetic variations involved in innate immunity are thought to be the most probable factor predisposing individuals to the development of TB (29) and may play a significant role in the modulation of immune responses to MTB infection and the clinical progression of TB (30).

Mutations in TLR producing genes could cause structural and functional changes in these receptors, altering immunological responses and influencing disease development (31). The ability of certain individuals to respond properly to TLR ligands may be impaired by SNPs within TLR genes that affect immune regulation, resulting in a shift in balance between pro- and anti-inflammatory cytokines and altered susceptibility to the infectious disease that might contribute to the pathogenesis of complex diseases including TB (32, 33). This allows the bacterium to evade elimination by the immune system, and the disease subsequently progresses (34).

Genetic variations, especially SNPs, can affect the development of disease in individuals and responses to pathogens, drugs, and vaccines (35). In Ethiopia, even though it has a significant health impact, there is no genetic evidence published in the country related to the TLR gene polymorphisms of TB infected people. Thus, this study aimed to determine potential genetic biomarkers of TLR2 gene with the susceptibility of PTB patients in Northwest Ethiopia. The difference in polymorphism within genes involved in the host immune response has been proposed as a plausible reason to explain why some people resist infection more successfully than others and play a major role in determining differential susceptibility to major infectious diseases (36, 37).

The identification of SNPs in host genes associated with susceptibility and resistance to TB plays an important role in investigating potential mechanisms underlying host immune responses to TB disease and will provide a rational basis for developing new approaches to treatment or novel therapies to treat the diseases (34, 36, 38). To date, several studies have already investigated the potential association between genetic polymorphisms in TLRs and susceptibility to TB in several human populations. However, results are in many instances inconsistent and inconclusive, especially when they were conducted in different populations, geography, and environments (39, 40), emphasizing the need for more studies from different human populations (40).

It was believed the study has ultimately hope that through genetic testing, individuals infected for TB will be identified before the onset of the disease – at a time when primary prevention strategies would be safely administered. It is most likely that such predictive genetic testing would be offered to individuals with LTBI before it was made available to the general population. It will add value to our current perspectives of treating, promising vaccine design, or preventing TB diseases. As far as we know, there has not been a study on the TLR2 gene polymorphism-related genetic risk factors for PTB in Ethiopia. Hence, this study aimed to assess the association between TLR2 gene polymorphisms and the susceptibility of PTB patients in Northwest, Ethiopia. In this study, the genotype distribution of T597C and G2258A was determined, and their association with PTB disease susceptibility was analyzed.

2 Method and Material#

2.1 Study area#

The study was conducted in the TB clinic at the University of Gondar comprehensive specialized hospital. The hospital is located in the Central Gondar zone, Gondar Town Administration. The town is located in Amhara National Regional State, 727 kilometers (km) from Addis Ababa, the capital city of Ethiopia. The town is situated at a latitude and longitude of 12° 36′ N and 37° 28′ E, respectively, with an elevation of 2133 meters above sea level. Currently, the population of Gondar town in 2023 is estimated to be 413,000 (41).

The University of Gondar comprehensive specialized hospital is one of the oldest health institutions in Ethiopia, produces many professionals, and has also given huge service to the community since 1954 (42). It is a multidisciplinary, specialized teaching hospital with more than 1,000 beds and approximately 2,000 members of staff. Currently, it provides health care services for more than seven million inhabitants in its catchment area (43). The TB clinic is one of the services delivered by the hospital for the diagnosis of patients with suspected TB, and it provides anti-TB treatment.

2.2 Study design and study period#

A case control study was conducted at UoGCSH from March 5, 2022, to March 30, 2023.

2.3 Source population#

All adult TB patients visiting the TB clinic at the UoGCSH were used as the source population.

2.4 Study population#

All adult patients confirmed with PTB in the TB clinic were taken as case groups during the study period. In addition, people who have no history of TB or active TB diseases collected from Gondar blood bank were taken as a control for the comparison groups.

2.5 Sample size and sampling techniques#

All eligible study participants who fulfilled the inclusion criteria during the study period were included. Thus, a convenient sampling technique was used, and a total of 101 study participants (35 PTB patients, 20 LTBI, and 46 HCs) were enrolled in the study.

2.6 Eligibility criteria#

2.7 Inclusion criteria#

Adult patients (age ≥ 18) confirmed with PTB during the study period were included as case groups in the study. Furthermore, adult individuals (age ≥ 18) who were free from clinical symptoms of active PTB and individuals with no medical history of TB were included as a control group in the study.

2.8 Exclusion criteria#

In case groups, a patient with extra-PTB was excluded. Moreover, individuals with known chronic diseases such as diabetes mellitus and rheumatoid arthritis and viral infections like HIV were excluded from the study.

Individuals with a history of TB, a history of anti-TB treatment, and clinical manifestations of active TB were excluded from control study participant recruitment. In addition, individuals with known chronic diseases such as diabetes mellitus and rheumatoid arthritis and viral infections like HIV were also excluded from the control group.

2.9 Data collection tool and laboratory procedure#

2.10 Socio-demographic and clinical data#

The data was collected by nurse professionals working in TB clinics. The socio-demographic and behavioral factor related data of PTB patients was collected through a face-to-face interview using structured questionnaires.

2.11 Blood specimen collection#

Under aseptic techniques, three milliliters and seven milliliters of venous blood were collected from PTB patients and asymptomatic healthy individuals, respectively. Four milliliters of blood from asymptomatic healthy individuals were distributed to four QFT test tubes (one ml for each tube) for LTBI screening, and the remaining three ml from asymptomatic healthy individuals and PTB patients’ blood were transferred to EDTA test tubes by following the appropriate blood collection procedure. The blood in the EDTA tube was properly mixed with anticoagulants to avoid blood clots before laboratory investigations were made. Each tube was labeled with a unique patient code for easy identification. The blood samples in the EDTA tube were kept under -800C until DNA isolation was done.

2.12 QuantiFERON-TB Gold plus Assay#

The QuantiFERON-TB Gold Plus assay (Qiagen, Germany) was used to measure IFN-γ production from T cells following in vitro stimulation with MTB specific antigens, including ESAT-6 and CFP-10). Four milliliters (4 ml) of blood were transferred to four separate tubes labeled as (Nil, MTB antigen-1, MTB antigen-2, and Mitogen) for antigen stimulation, which were then incubated for 20 hours. The Mitogen tube was used as a positive control, while the nil tube was used to adjust the background value for non-specific IFN-γ detection in blood samples by subtracting from the TB antigen tubes and Mitogen tubes. After a period of incubation, the tubes were centrifuged at 2500 relative centrifugal force (RCF) for 15 minutes, and the plasma samples were separated and transferred into a Nunc tube, and stored at -800 C until transported to Armaur Hansen Research Institute (AHRI), Addis Ababa, with the appropriate cold chain system for IFN-γ analysis. Finally, the presence of LTBI was determined by measuring IFN-γ from plasma using an enzyme-linked immunosorbent assay (ELISA), and the results were interpreted using the TB QFT version 2.71.2 software (44).

2.13 DNA extraction#

The DNA extraction was done on the whole blood samples collected from study participants using the automated Maxwell® 16 kit (Promega Corporation, USA), following the manufacturer’s instructions. The Maxwell® 16 instrument purifies samples using a novel paramagnetic particle, that provides a mobile solid phase that optimizes sample capture, washing, and purification of gDNA (45). Three hundred microliters (µl) of whole blood were added to the tube, and then 300 µl of lysis buffer and 30 µl of proteinase K were added and vortexed for 10 seconds, followed by a quick spine for 15 seconds. Then, it was incubated at 56 0C for 20 minutes at 400 rpm (45).

In the meantime, the Maxwell® 16 cartridge was prepared as follows: The cartridges were placed in the Maxwell 16 cartridge rack and then pressed down on the cartridge to snap it into position. Empty elution tubes were placed for each cartridge, and then 60 µl of elution buffer was added to each elution tube. The seal was carefully peeled back only to the upper first well, and all the incubated material of each sample was transferred to well #1 of each cartridge, and one plunger was placed into the well of each cartridge. Finally, the rack was placed in the Maxwell extractor, and the extraction run started. Following the extraction, the extracted product was transferred to the tube and stored at -80 0C until the PCR amplification (45). The extracted DNA concentrations were measured using a Quibit fluorometer (Invitrogen, USA) (46).

2.14 Tag SNP and its primer sequence selection#

We searched the SNP locations of TLR2 gene in the SNP database of the National center for Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih.gov/SNP). Moreover, based on previously published data on the association of TLR-2 gene with the susceptibility of TB from different studies, two SNPs from TLR-2 genes (G2258A and T597C), were selected. The SNP selection was based on their location, possible functional effect, and associations with PTB diseases.

We used four primers (two external primers and two inner primers) for each SNP. Primer sequences were taken from previous literature, and the primer sequence details for all variants are provided in Table 1. Primers were purchased as lyophilized oligonucleotides (Sigma Aldrich, Germany), and then reconstituted with sterile deionized water to make 100µM concentrations of stock solution. Then, dilutions were made from this stock to reach 10µM and 20 µM working solution and stored at -20 0C.

2.15 Genotyping of TLR-2 SNPs by PCR#

Genomic DNA extraction from whole blood samples was carried out for genotyping SNPs of TLR2 and TLR4 using the tetra- allele refractory mutation system (T-ARMS)-based PCR method, which only involves a single PCR followed by gel electrophoresis (50). The SNPs were amplified using conventional PCR (TechenTC-412/Keison Products, England) targeting the TLR2 G2258A and T597C gene variants.

The TLR 2 +2258 (G/A) amplification, a 25 μl reaction volume made of 20 µl of master mix (8.7 µl molecular grade water, 2.5 µl 10x PCR buffer, 1.5 µl of 50 Mm MgCl 2, 1.5 µl of each primer (20 μM of both OF and OR and 10 μM of IF and IR (Sigma Al drich, Germany), 1 µl of 10 mM of each dNTP, and 0.3 µl of 5 unit Taq DNA polymerase) and 5µl of the template DNA were used for conventional PCR. A non-template master mix as a negative control was performed in parallel with the samples. Then the tubes were inserted into the thermocycler and run with the program of 95 0C for 5 min of initial denaturation, 40 cycles of 95 0C for 30 sec, 60 0C for 45 sec, and 72 0C for 1 min, and then a final extension at 72 0C for 10 minutes for template amplification.

The TLR 2 +597 (T/C) amplification by thermocycler was achieved using a reaction volume of 25μl containing about 1.5μl of 10 μM of each OF and OR and 1.5 μl of 20μM of each IF and IR, 8.7 μl of PCR water, 2.5 μl of 10x PCR buffer, 1.5 μl of 50 mM MgCl 2, 1μl of 10 mM of each dNTP, 0.3 μl of 5 unit Taq DNA polymerase (Invitrogen, USA) and 5μl template DNA. Amplification was carried out using the PCR conditions of initial denaturation at 94 0C for 5 minutes, followed by 40 cycles of denaturation at 95 0C for 1 minute, annealing at 60 0C for 30 seconds, extension at 72 0C for 30 seconds, followed by a final extension at 72 0C for 10 minutes to allow for complete extension of all PCR fragments.

2.16 Gel electrophoresis#

PCR products are subjected to gel electrophoresis on a 2% agarose gel stained with Modri Green advanced DNA staining dye to visualize DNA in an ultraviolet (UV) trans illuminator to determine the allele and genotype frequency of the PCR product (51). The obtained pattern was analyzed against 50- bp DNA ladders (available commercially).

2.17 Data and sample quality control#

The data collection tool developed from different studies was prepared in English, and translated to the local Amharic language, and then re-translated back to English. Before the actual work, training was given to data collectors to assure that it would be proper and understandable about the objective and relevance of the study, confidentiality issues, the rights of study participants, and result recording. Another orientation was also given about blood specimen collection, storage, and processing. The principal investigator makes daily checkups and monitors to ensure the completeness and consistency of the information collected and sample collection procedures.

The pre-analytical, analytical, and post-analytical phases of quality assurance were carried out during sample processing by carefully following standard operating procedures (SOPs). SOPs and manufacturer instructions were strictly followed throughout the procedures, and all reagents were stored and prepared according to the manufacturer’s instructions.

2.18 Data processing and analysis#

After collection, the data were reviewed, coded, and entered into Epi-Data Manager Version 4.6 software and exported into the SPSS 25 version (IBM Corporation, Armonk, NY, USA) statistical software for analysis. The result was summarized using descriptive statistics. The categorical variables were calculated using the chi-square test between the studied groups. Continuous variables such as age and BMI were expressed as “mean ± standard deviation (SD)”. The genotype and allele frequencies were computed in groups using chi- square cross-tabulation. Binary and multivariable logistic regression analyses were used to determine the association between selected SNPs in the TLR2 gene polymorphisms and PTB. The crude odd ratio (COR) and adjusted odd ratio (AOR) with 95% CI were used to express the strength of the association. A result was considered statistically significant with a p-value of less than 0.05. SNPStats online software [available online: https://www.snpstats.net/start.htm (accessed on September 19, 2022)] was used to calculate the HWE (52).

3 Results#

3.1 Socio-demographic characteristics of study participants#

A total of 101 participants (35 PTB patients, 20 LTBI, and 46 HCs) were enrolled in this study. The sex distributions were 59 (58.4%) males and 42 (41.6%) females in the three groups. The mean ages of the participants were 30.94±9.63 for all study participants. In addition, the mean BMI for the study participant was 19.47±2.14 for PTB, 20.74±1.29 for LTBI, and 20.49±1.9 for HC (Table 2).

3.2 Clinical characteristics of PTB patient participants#

Clinical data from PTB patients, such as signs and symptoms of PTB, were collected from the patient’s medical chart. From the total of 35 PTB-infected study participants, 34 (97.14%) had coughs, and 24 (68.57%) had night sweats (Table 3).

3.3 Distribution of TLR2 (T597C and G2258A) gene polymorphisms in the study participants#

We evaluated the HWE using SNP Stat online software for each detected SNP before the genetic association analysis with PTB diseases. As outlined in Table 4, the genotype frequencies of T597C did not deviate from the HWE in PTB (p = 0.12), LTBI (p = 0.67), and HC (p = 0.1) participants.

The genotypes and allele frequencies in TLR2 G2258A and T597C polymorphisms among PTB, LTBI and HC study participants

The TLR2 G2258A and T597C gene polymorphisms were performed in 101 study subjects. The distributions of TLR2 (+597T/C) CC mutated homozygote, TC heterozygote, and TT wild-type homozygote genotypes were 50 (49.5%), 27 (26.7%), and 24 (23.8%), respectively, among all study participants. In PTB patients, the frequencies of the TT genotype were 5 (14.3%), the TC genotype was 7 (20.0%), and the CC genotype was 23 (65.7%). Genotypic frequencies of TLR2 gene polymorphisms at (+597T/C) among LTBI and controls are presented in Table 4.

Regarding allele frequencies, all study participants were more likely to have a mutated (C) allele as compared to a wild-type (T) allele, with frequencies of 123 (60.9%) and 79 (39.1%), respectively. Furthermore, the mutated-type (C) allele frequency was found to be high in PTB patients 53 (75.7%) when compared with LTBI 21 (52.5%) and HCs 49 (53.3%) (Table 4).

The G2258A SNP in the TLR2 gene was not detected in all study participants. Only the wild-type G allele was observed in PTB, LTBI, and HC, as shown in Figure 1b.

1A

1B

3.4 Association between TLR2 SNPs with PTB patients#

3.5 Association of TLR2 gene polymorphisms at T597C with PTB patients#

We assessed the associations of the TLR2 T597C polymorphism in three groups using a binary and multivariable logistic regression model (Table 5). The regression analysis revealed that the genotype CC in T597C had a significant association with PTB as compared to HC groups (AOR = 4.54, 95% CI = 1.18–11.92, p = 0.028). The C allele in the TLR2 597T/C polymorphism also showed an association with PTB as compared to LTBI (AOR = 2.77, 95% CI = 1.2–6.42, p = 0.017) and HC (AOR = 3.4, 95% CI = 1.6–7.1, p = 0.001).

Note : AOR^a , Adjusted odd ratio for age and body mass index; AORb, Adjusted odd ratio for age, sex, and body mass index; COR, Crude odd ratio; LTBI, latent tuberculosis infection; PTB, pulmonary tuberculosis; TLR, Toll like receptor; SNP, Single nucleotide polymorphism; ref, reference.

4 Discussion#

Host genetics play a critical role in resistance or susceptibility to MTB infection. The host’s innate immune response is the first line of defense against invading pathogens and is vital for the initial defense against MTB and the activation of the adaptive immune response (53). Since the TLR-encoding genes play an important role in host immunity, variants of these genes cause an altered immune response and affect the progression of TB disease. Among these, various studies have identified TLR2 gene variants (T597C and G2258A) that influence PTB risk. However, the direct evidence remains controversial. In the present study, we analyzed the association between TLR2 (T597C and G2258A) gene polymorphisms and susceptibility to PTB in 101 study participants.

The synonymous T597C polymorphisms in the TLR2 gene coding region are associated with susceptibility to PTB disease. Therefore, we analyzed the TLR2 T597C (Asn¹⁹⁹ Asn) gene variant in association with PTB. The mutated CC genotype of the T597C TLR-2 gene polymorphism in PTB patients, LTBI, and HC groups was found at 23 (65.7%), 6 (30%), and 21 (45.6%), respectively. We also found that the distribution of the C allele in PTB had a higher frequency distribution than in the LTBI and HC groups (Table 4). The C allele and CC genotype of the T597C-TLR2 gene were significantly associated with PTB patients compared to HC (p = 0.001 and p = 0.028, respectively). These basic findings are consistent with scientific insights that the synonymous SNP T597C located in the TLR2 coding exon can directly alter mRNA transcription and splicing, affect the expression of remaining exons within the genes, the stability of mRNA, and modulate mRNA structure and protein folding (54, 55, 56). Unstable RNA due to synonymous variation has a shorter functional half-life and results in low protein levels (57). Therefore, effects on protein expression can impair the host’s immune response (58). In accordance, a previous study suggested that the synonymous T597C mutations are associated with down-regulated transcription of TLR2 and decreased TLR2 expression levels. Moreover, they reported that the carriers of a CC genotype mutation had significantly lower levels of pro-inflammatory cytokines (IL-6 and TNF-α) than carriers of wild-type TT genotypes of the T597C polymorphism (59). This attenuates the host’s innate immune response, and results in decreased macrophage function in response to infection with MTB and a greater chance of developing TB (21). This finding is consistent with a previous study conducted in the Sudanese (25), Egyptian (60), and Iranian (49) populations.

Contrary to our finding, a study showed that the C allele and CC genotype did not show a significant association with PTB among the Chinese (61), Han Chinese and Tibetan Chinese (29, 62), Mongolian (63), Colombian (64), and Mexican (65) populations. TLR2 polymorphism +597T/C were not associated with TB. The considerable differences in this polymorphism among different populations might explain such a discrepancy.

On the other hand, a previous study depicted that the TLR2 +597 T/C mutated genotype was associated with protection against PTB. A study conducted in the Moroccan (66), Moldavian (67), and Chinese Tibetan populations (68) showed that the TLR2 +597 T/C genotype was associated with protection against PTB. Such discrepancies could result from different environmental and pathogen-induced selection pressures, potential differences in the involved MTB strains, and race-specific differences in the patterns of evolutionary distribution.

In this study, we also analyzed the TLR2 G2258A (Arg⁷⁵³ Gln) gene variant in association with PTB. We did not find the mutated (A) allele in any of the study groups (PTB patients, LTBI, or HCs). Although the G2258A polymorphism of TLR2 is not found in our study, it is a missense variant that affects the structure of the TLR-2 protein in the intracellular domain and produces a non-functional protein since at position 753 of the protein (Arg⁷⁵³ Gln), the amino acid arginine is replaced by glutamine (69). Then, this variant can lead to failures in the recognition mechanisms of mycobacterial antigens. This alteration resulted in impaired TLR2 tyrosine phosphorylation,TLR2-TLR6 dimerization, recruitment of MyD88, repression of transcription factors such as NF-B activation, and reduced secretion of key inflammatory mediators (17).

Similar evidence consistent with our findings has been reported in various studies. The absence of the TLR2 G2258A mutated allele in this study is in line with the results of a study conducted in the Sudanese (70), Iranian (71), Mexican (65), and Brazilian (72) populations. However, in studies conducted in the Sudan (25), Egypt (73), and Chinese (61) population, the TLR-2 Arg⁷⁵³ Gln SNP was reported as associated with PTB disease. The discrepancies between the aforementioned results may be attributed to the different sample sizes and ethnicities.

The main strength of this study is that it can be considered as a benchmark and a preliminary study in Ethiopia that gives baseline information on the genetic and immunological markers of TLR2 gene polymorphisms as risk factors for PTB patients in Ethiopian populations. We identified individuals with LTBI in the HCs, which may strengthen our statistical power to identify potential susceptibility at the locus.

However, we have not analyzed how SNPs influence susceptibility to progression from LTBI to active TB disease, and thus the underlying mechanisms remain to be explored. Second, we used a small sample size, which may limit the statistical power of the study. Thirdly, as with many possible genetic factors, we have not analyzed the probable causes of TB on a large scale in the community.

5 Conclusion#

In this study, the CC mutant homozygote genotypes in T597C of the TLR2 are more frequent among PTB patients than LTBI and HC groups and are significantly associated with PTB when compared with HC participants. In addition, the mutated C allele frequency was high and statistically significant with PTB. This considerable association of the T597C CC genotype and C allele with PTB gives us insight into its role in the susceptibility of PTB.

The G2258A polymorphism of the TLR-2 gene is monomorphic (only the G (wild-type) allele is detected) in all study participants (PTB, LTBI, and HCs groups).

6 Recommendation#

Based on our findings, the following recommendations are forwarded to the researcher:

• This study shows the T597C is associated with the susceptibility to PTB in our study populations, therefore, to come up with a compressive conclusion, it needs a large sample size using a community-based cohort study to clarify the association of these gene variant with PTB in in different parts of Ethiopia.
• We recommend, this study should include additional SNP in TLR2 (like Arg677Trp and Pro631His), and other TLR polymorphisms found in TLR1, TLR4, TLR6, and TLR9 to clarify the association of these TLR genes with PTB.
• We recommend further studies to perform haplotype analyses and explore potential gene-gene interactions.
• We found that the mutated C allele was overrepresented in the study groups. Therefore, it is recommended to evaluate the T597C polymorphism of the TLR-2 gene through sequencing analysis.